Profitability ratios measure the company ability to generate profitable sales from its resources (assets).
Profitability Ratios (Summary)
Return on Sales
Return on Investment
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
The financial performance from 2019 to 2023 is characterized by extreme volatility, marked by a period of exceptional profitability between 2021 and 2022 followed by a sharp contraction in 2023.
- Profit Margin Trends
- Gross profit margins experienced a continuous and significant decline after peaking at 96.03% in 2020, falling steadily to 29.65% by 2023. Operating and net profit margins exhibited severe fluctuations; both indicators recorded deep deficits in 2020, surged to peak levels in 2021—75.22% for operating and 69.04% for net profit—and subsequently returned to negative territory in 2023, reaching -63.54% and -70.66%, respectively.
- Asset and Equity Returns
- Return on Equity (ROE) and Return on Assets (ROA) followed a symmetrical trajectory of rapid ascent and decline. ROE transitioned from -43.75% in 2019 to a peak of 86.26% in 2021, before descending to -34.03% in 2023. Similarly, ROA moved from -32.34% in 2019 to a high of 49.46% in 2021, eventually declining to -25.58% by the end of the period.
The correlation between the compression of gross margins and the collapse of net profit margins suggests a substantial increase in the cost of goods sold relative to revenue, alongside escalating operating expenses. This combination resulted in the complete reversal of the profitability gains observed during the 2021-2022 window.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Gross Profit Margin
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Gross profit | 1,978) | 13,019) | 15,058) | 192) | —) | |
| Net product sales | 6,671) | 18,435) | 17,675) | 200) | —) | |
| Profitability Ratio | ||||||
| Gross profit margin1 | 29.65% | 70.62% | 85.19% | 96.03% | — | |
| Benchmarks | ||||||
| Gross Profit Margin, Competitors2 | ||||||
| AbbVie Inc. | 62.42% | 70.00% | 68.96% | — | — | |
| Amgen Inc. | 68.60% | 74.17% | 73.44% | — | — | |
| Bristol-Myers Squibb Co. | 76.24% | 78.04% | 78.57% | — | — | |
| Danaher Corp. | 58.74% | 60.21% | 60.95% | — | — | |
| Eli Lilly & Co. | 79.25% | 76.77% | 74.18% | — | — | |
| Gilead Sciences Inc. | 75.87% | 79.03% | 75.56% | — | — | |
| Johnson & Johnson | 68.82% | 67.26% | 68.16% | — | — | |
| Merck & Co. Inc. | 73.17% | 70.63% | 72.02% | — | — | |
| Pfizer Inc. | 58.10% | 66.05% | 62.48% | — | — | |
| Regeneron Pharmaceuticals Inc. | 86.16% | 87.18% | 84.83% | — | — | |
| Thermo Fisher Scientific Inc. | 39.90% | 42.24% | 50.08% | — | — | |
| Vertex Pharmaceuticals Inc. | 87.21% | 87.90% | 88.06% | — | — | |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
Gross profit margin = 100 × Gross profit ÷ Net product sales
= 100 × 1,978 ÷ 6,671 = 29.65%
2 Click competitor name to see calculations.
An analysis of the financial performance from 2020 to 2023 reveals a period of extreme volatility in revenue and a consistent, accelerating decline in profitability margins.
- Net Product Sales Trends
- Net product sales experienced an exponential surge between 2020 and 2021, growing from US$ 200 million to US$ 17,675 million. Revenue peaked in 2022 at US$ 18,435 million before undergoing a sharp contraction in 2023, falling to US$ 6,671 million.
- Gross Profit Analysis
- Gross profit mirrored the rapid expansion of sales, peaking in 2021 at US$ 15,058 million. Subsequently, a downward trajectory began in 2022 with a decrease to US$ 13,019 million, followed by a precipitous drop to US$ 1,978 million in 2023.
- Gross Profit Margin Erosion
- A continuous downward trend in the gross profit margin is observed throughout the reported period. The margin declined from 96.03% in 2020 to 85.19% in 2021, and further to 70.62% in 2022. The most severe erosion occurred in 2023, with the margin collapsing to 29.65%, indicating that costs of production increased significantly relative to net sales during this final period.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Operating Profit Margin
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Income (loss) from operations | (4,239) | 9,420) | 13,296) | (763) | (546) | |
| Net product sales | 6,671) | 18,435) | 17,675) | 200) | —) | |
| Profitability Ratio | ||||||
| Operating profit margin1 | -63.54% | 51.10% | 75.22% | -381.82% | — | |
| Benchmarks | ||||||
| Operating Profit Margin, Competitors2 | ||||||
| AbbVie Inc. | 23.49% | 31.21% | 31.89% | — | — | |
| Amgen Inc. | 29.35% | 38.57% | 31.44% | — | — | |
| Bristol-Myers Squibb Co. | 16.18% | 17.96% | 15.91% | — | — | |
| Danaher Corp. | 21.77% | 27.61% | 25.35% | — | — | |
| Eli Lilly & Co. | 18.92% | 24.97% | 22.45% | — | — | |
| Gilead Sciences Inc. | 28.24% | 27.17% | 36.72% | — | — | |
| Johnson & Johnson | 24.90% | 24.63% | 24.95% | — | — | |
| Merck & Co. Inc. | 3.92% | 30.27% | 25.74% | — | — | |
| Pfizer Inc. | 2.15% | 35.37% | 24.70% | — | — | |
| Regeneron Pharmaceuticals Inc. | 30.85% | 38.93% | 55.67% | — | — | |
| Thermo Fisher Scientific Inc. | 16.00% | 18.69% | 25.57% | — | — | |
| Vertex Pharmaceuticals Inc. | 38.83% | 48.23% | 36.73% | — | — | |
| Operating Profit Margin, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 18.01% | 28.59% | 26.98% | — | — | |
| Operating Profit Margin, Industry | ||||||
| Health Care | 12.79% | 18.74% | 18.04% | — | — | |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
Operating profit margin = 100 × Income (loss) from operations ÷ Net product sales
= 100 × -4,239 ÷ 6,671 = -63.54%
2 Click competitor name to see calculations.
The operating profit margin exhibits extreme volatility over the observed five-year period, characterized by a rapid transition from early-stage losses to exceptional profitability, followed by a significant contraction.
- Initial Operating Loss Phase (2019-2020)
- An initial period of negative operating margins is observed, with income from operations declining from a loss of 546 million US dollars in 2019 to a loss of 763 million US dollars in 2020. The operating profit margin for 2020 reached -381.82%, reflecting high operational expenditures relative to the limited net product sales of 200 million US dollars recorded during that year.
- Peak Profitability Surge (2021-2022)
- A drastic reversal in profitability occurred in 2021, as net product sales surged to 17.675 billion US dollars. This resulted in an operating profit of 13.296 billion US dollars and a peak operating profit margin of 75.22%. While net product sales increased further to 18.435 billion US dollars in 2022, income from operations decreased to 9.420 billion US dollars, leading to a compression of the operating profit margin to 51.10%.
- Operating Contraction (2023)
- A sharp downward trend is evident in 2023, marked by a substantial decrease in net product sales to 6.671 billion US dollars. This revenue decline coincided with a return to operating losses, totaling 4.239 billion US dollars, which drove the operating profit margin back into negative territory at -63.54%.
The sequence of results indicates a high sensitivity of the operating margin to net product sales volumes, where the period of peak profitability was temporary and followed by a significant operational reset.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Net Profit Margin
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Net income (loss) | (4,714) | 8,362) | 12,202) | (747) | (514) | |
| Net product sales | 6,671) | 18,435) | 17,675) | 200) | —) | |
| Profitability Ratio | ||||||
| Net profit margin1 | -70.66% | 45.36% | 69.04% | -373.77% | — | |
| Benchmarks | ||||||
| Net Profit Margin, Competitors2 | ||||||
| AbbVie Inc. | 8.95% | 20.39% | 20.54% | — | — | |
| Amgen Inc. | 24.96% | 26.42% | 24.25% | — | — | |
| Bristol-Myers Squibb Co. | 17.83% | 13.71% | 15.08% | — | — | |
| Danaher Corp. | 19.94% | 22.91% | 21.84% | — | — | |
| Eli Lilly & Co. | 15.36% | 21.88% | 19.71% | — | — | |
| Gilead Sciences Inc. | 21.03% | 17.02% | 23.05% | — | — | |
| Johnson & Johnson | 41.28% | 18.90% | 22.26% | — | — | |
| Merck & Co. Inc. | 0.61% | 24.49% | 26.79% | — | — | |
| Pfizer Inc. | 3.56% | 31.01% | 26.76% | — | — | |
| Regeneron Pharmaceuticals Inc. | 30.14% | 35.64% | 50.25% | — | — | |
| Thermo Fisher Scientific Inc. | 13.99% | 15.47% | 19.70% | — | — | |
| Vertex Pharmaceuticals Inc. | 36.68% | 37.20% | 30.92% | — | — | |
| Net Profit Margin, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 17.95% | 22.55% | 23.38% | — | — | |
| Net Profit Margin, Industry | ||||||
| Health Care | 11.49% | 14.65% | 15.24% | — | — | |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
Net profit margin = 100 × Net income (loss) ÷ Net product sales
= 100 × -4,714 ÷ 6,671 = -70.66%
2 Click competitor name to see calculations.
The financial performance from 2019 to 2023 is characterized by extreme volatility in both net income and net profit margins. The period exhibits a rapid transition from operational losses to exceptional profitability, followed by a sharp reversal back into a deficit position.
- Net Income Trajectory
- Operational losses were recorded in 2019 and 2020, with the deficit deepening to US$ 747 million in 2020. A substantial reversal occurred in 2021, where net income peaked at US$ 12,202 million. While profitability remained strong in 2022 at US$ 8,362 million, the trend reversed sharply in 2023, resulting in a net loss of US$ 4,714 million.
- Net Product Sales Performance
- Revenue experienced explosive growth, rising from US$ 200 million in 2020 to a peak of US$ 18,435 million in 2022. However, a significant contraction is observed in 2023, with sales falling to US$ 6,671 million, representing a decrease of approximately 63.8% compared to the prior year.
- Net Profit Margin Fluctuations
- The net profit margin shows extreme variance, shifting from -373.77% in 2020 to a high of 69.04% in 2021. A subsequent compression is noted in 2022, with the margin declining to 45.36%. By 2023, the margin plummeted to -70.66%, indicating that costs and expenses significantly exceeded generated revenues during that period.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Return on Equity (ROE)
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Net income (loss) | (4,714) | 8,362) | 12,202) | (747) | (514) | |
| Stockholders’ equity | 13,854) | 19,123) | 14,145) | 2,561) | 1,175) | |
| Profitability Ratio | ||||||
| ROE1 | -34.03% | 43.73% | 86.26% | -29.17% | -43.75% | |
| Benchmarks | ||||||
| ROE, Competitors2 | ||||||
| AbbVie Inc. | 46.94% | 68.60% | 74.91% | — | — | |
| Amgen Inc. | 107.78% | 178.97% | 87.96% | — | — | |
| Bristol-Myers Squibb Co. | 27.27% | 20.37% | 19.46% | — | — | |
| Danaher Corp. | 8.91% | 14.39% | 14.24% | — | — | |
| Eli Lilly & Co. | 48.65% | 58.64% | 62.16% | — | — | |
| Gilead Sciences Inc. | 24.81% | 21.62% | 29.55% | — | — | |
| Johnson & Johnson | 51.11% | 23.36% | 28.20% | — | — | |
| Merck & Co. Inc. | 0.97% | 31.57% | 34.17% | — | — | |
| Pfizer Inc. | 2.38% | 32.79% | 28.47% | — | — | |
| Regeneron Pharmaceuticals Inc. | 15.22% | 19.14% | 43.03% | — | — | |
| Thermo Fisher Scientific Inc. | 12.83% | 15.80% | 18.94% | — | — | |
| Vertex Pharmaceuticals Inc. | 20.59% | 23.88% | 23.19% | — | — | |
| ROE, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 20.65% | 27.99% | 29.75% | — | — | |
| ROE, Industry | ||||||
| Health Care | 19.40% | 24.82% | 25.44% | — | — | |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
ROE = 100 × Net income (loss) ÷ Stockholders’ equity
= 100 × -4,714 ÷ 13,854 = -34.03%
2 Click competitor name to see calculations.
The financial trajectory between 2019 and 2023 is characterized by extreme volatility in profitability, with return on equity (ROE) shifting from deep negative territory to an exceptional peak before returning to a deficit.
- Return on Equity (ROE) Trends
- ROE exhibited a drastic fluctuation over the five-year period. After starting at -43.75% in 2019 and improving slightly to -29.17% in 2020, the ratio surged to a peak of 86.26% in 2021. This indicates a period of extraordinary capital efficiency. However, this trend reversed rapidly, with ROE declining to 43.73% in 2022 and falling back to -34.03% by the end of 2023.
- Correlation with Net Income
- The volatility in ROE is directly driven by substantial swings in net income. Net losses of 514 million and 747 million in 2019 and 2020, respectively, were followed by a massive increase to 12.2 billion in 2021. While profitability remained high in 2022 at 8.36 billion, a significant reversal occurred in 2023 with a net loss of 4.71 billion, which precipitated the negative ROE.
- Stockholders' Equity Dynamics
- The equity base experienced consistent growth from 2019 through 2022, increasing from 1.18 billion to 19.12 billion. This expansion of the equity denominator contributed to the reduction of ROE in 2022, as the profit growth did not keep pace with the increase in equity. In 2023, stockholders' equity contracted to 13.85 billion, as the net loss eroded the accumulated retained earnings.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Return on Assets (ROA)
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Net income (loss) | (4,714) | 8,362) | 12,202) | (747) | (514) | |
| Total assets | 18,426) | 25,858) | 24,669) | 7,337) | 1,589) | |
| Profitability Ratio | ||||||
| ROA1 | -25.58% | 32.34% | 49.46% | -10.18% | -32.34% | |
| Benchmarks | ||||||
| ROA, Competitors2 | ||||||
| AbbVie Inc. | 3.61% | 8.53% | 7.88% | — | — | |
| Amgen Inc. | 6.91% | 10.06% | 9.63% | — | — | |
| Bristol-Myers Squibb Co. | 8.43% | 6.53% | 6.40% | — | — | |
| Danaher Corp. | 5.64% | 8.55% | 7.73% | — | — | |
| Eli Lilly & Co. | 8.19% | 12.62% | 11.44% | — | — | |
| Gilead Sciences Inc. | 9.12% | 7.27% | 9.16% | — | — | |
| Johnson & Johnson | 20.98% | 9.57% | 11.47% | — | — | |
| Merck & Co. Inc. | 0.34% | 13.30% | 12.35% | — | — | |
| Pfizer Inc. | 0.94% | 15.91% | 12.11% | — | — | |
| Regeneron Pharmaceuticals Inc. | 11.95% | 14.85% | 31.75% | — | — | |
| Thermo Fisher Scientific Inc. | 6.07% | 7.15% | 8.12% | — | — | |
| Vertex Pharmaceuticals Inc. | 15.92% | 18.30% | 17.44% | — | — | |
| ROA, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 7.25% | 10.67% | 10.42% | — | — | |
| ROA, Industry | ||||||
| Health Care | 7.19% | 9.66% | 9.46% | — | — | |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
ROA = 100 × Net income (loss) ÷ Total assets
= 100 × -4,714 ÷ 18,426 = -25.58%
2 Click competitor name to see calculations.
The financial performance from 2019 to 2023 demonstrates extreme volatility in profitability and asset utilization, characterized by a sharp period of growth followed by a substantial correction.
- Net Income Volatility
- Operations were initially characterized by net losses, with a deficit of 514 million US dollars in 2019 increasing to 747 million US dollars in 2020. A dramatic shift occurred in 2021, as net income surged to 12.2 billion US dollars. This profitability moderated to 8.36 billion US dollars in 2022 before reverting to a net loss of 4.71 billion US dollars in 2023.
- Asset Base Expansion and Contraction
- A rapid expansion of the asset base is observed between 2019 and 2022, with total assets growing from 1.59 billion US dollars to a peak of 25.86 billion US dollars. This represents a significant accumulation of resources during the company's peak earning years. By the end of 2023, the asset base contracted to 18.43 billion US dollars.
- Return on Assets (ROA) Trends
- The ROA closely mirrored the fluctuations in net income, shifting from -32.34% in 2019 to a peak of 49.46% in 2021. In 2020, the ROA improved to -10.18% despite an increase in net losses, a trend driven by the substantial increase in the asset base which diluted the impact of the losses. The subsequent decline to 32.34% in 2022 and the sharp drop to -25.58% in 2023 indicate a severe erosion of asset efficiency and a return to negative returns on invested resources.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?